VX-864

DRUG2 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Alpha-1 Antitrypsin DeficiencyAlpha1-Antitrypsin Deficiency

Phase 2

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

CompletedNCT04474197

Vertex Pharmaceuticals IncorporatedAlpha1-Antitrypsin Deficiency

Start: 2020-07-24End: 2021-05-04Updated: 2022-05-26

A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

TerminatedNCT05643495

Vertex Pharmaceuticals IncorporatedAlpha-1 Antitrypsin Deficiency

Start: 2023-02-23End: 2024-08-19Updated: 2025-09-08